Gene Expression Signature to predict early development of brain metastasis in lung adenocarcinoma.

e19064 Background: Advances in systemic treatment have substantially improved the overall survival of advanced lung adenocarcinoma patients, and risk of brain metastases(BM) is higher. The survival of patients with symptomatic BM is poor. The identification of NSCLC patients with a high risk of developing BM would enable pre-emptive intervention to improve the outcome. Methods: A total of 53 biopsies of primary lung tumor adenocarcinoma stage IV treatment-naive were analyzed for gene expression profiling using Affymetrix HuGene 1.0 ST and were processed in R using Bioconductor libraries. All patients were evaluated with brain MRI at diagnosis with a 3-month follow-up for BM development. Patients were classified into two groups: early-BM( 6 months). A second independent cohort of 55 patients was analyzed to validate the gene expression signature (ClinicalTrials.gov: NCT00862173). Results: Samples were classified as early-BM(17) and late-BM(6), the remainder 30 never developed BM....